Latest News and Press Releases

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma’s continued maturation as the...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeksDurable effects...

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release...

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference:...

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder...

Ex presidente de la división de farmacéutica especializada de Shire PLC (“Shire”), con más de 30 años de experiencia en neurociencia, enfermedades raras y productos farmacéuticos especializados,...

Bekas Presiden perniagaan Farmaseutikal Khusus Shire PLC (“Shire”), dengan lebih 30 tahun pengalaman merentasi bidang neurosains, penyakit jarang jumpa dan farmaseutikal khusus, termasuk memegang...

Shire PLC(“Shire”) 전문의약품 사업부 전 사장으로, 신경과학·희귀질환·전문의약품 분야에서 30년 이상 경력 보유, Astra-Merck 및 AstraZeneca PLC에서 고위 리더십 역할 수행중추신경계(CNS) 프로그램 전반에 걸친 후기 임상 개발, 글로벌 상업화 및 자본 조달 분야에서 입증된 리더이번 분기 HLP004의 2상 데이터 발표...

シャイアーPLC (Shire PLC) (以下「シャイアー」) スペシャリティ医薬品事業部門の元社長であり、アストラ・メルク (Astra-Merck) およびアストラゼネカ (AstraZeneca PLC) でも上級管理職を務め、神経科学、希少疾患、スペシャリティ医薬品分野において30年以上の経験中枢神経系 (以下「CNS」)...

曾出任 Shire PLC（簡稱「Shire」）專科製藥業務總裁，在神經科學、罕見疾病及專科製藥範疇擁有 30 多年豐富經驗，曾於 Astra-Merck 及 AstraZeneca PLC 擔當高層領導職務在中樞神經系統（簡稱「CNS」）項目的後期臨床開發、全球商業化及資金募集方面具備有目共睹的領導才能此任命正值 Helus Pharma...